{
    "nct_id": "NCT06140836",
    "official_title": "Randomized, Open-label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)",
    "inclusion_criteria": "* Participant has histologically or cytologically confirmed diagnosis of locally advanced or metastatic NSCLC\n* Participant has a ROS1 gene rearrangement/fusion as detected by a local test.\n* At least 1 measurable lesion according to RECIST v1.1, as assessed by the investigator.\n* Participants must not be exposed previously with TKIs that demonstrated activities in ROS1-positive NSCLC\n* Up to 1 prior line of systemic treatment for NSCLC is permitted\n* ECOG Performance Status ≤ 2\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Symptomatic brain metastases or symptomatic leptomeningeal involvement.\n* History of previous cancer requiring therapy within the previous 2 years, except for NSCLC under study, squamous cell or basal-cell carcinoma of the skin, or any in situ carcinoma that has been completely resected.\n* Known tumor targetable co-mutations or rearrangements\n* Clinically significant cardiovascular disease (either active or within 6 months prior to enrollment)\n\nNote: Other protocol-defined inclusion/exclusion criteria apply",
    "miscellaneous_criteria": ""
}